(1) Background: Viral hepatitis C (HCV) and viral hepatitis B (HBV) are common co-infections in people living with HIV (PLWH). All PLWH should be vaccinated against HBV and hepatitis A (HAV) and treated for HBV and HCV. We aimed to compare testing, prophylaxis and treatment of viral hepatitis in PLWH in Central and Eastern Europe (CEE) in 2019 and 2022. (2) Methods: Data was collected through two on-line surveys conducted in 2019 and 2022 among 18 countries of the Euroguidelines in CEE (ECEE) Network Group. (3) Results: In all 18 countries the standard of care was to screen all PLWH for HBV and HCV both years; screening of HAV was routine in 2019 in 54.5% and in 2022 47.4% of clinics. Vaccination of PLWH against HAV was available in 2019 in 16.7%, in 2022 in 22.2% countries. Vaccination against HBV was available routinely and free of charge in 50% of clinics both in 2019 and 2022. In HIV/HBV co-infected the choice of NRTI was tenofovir-based in 94.4% of countries in both years. All clinics that responded had access to direct-acting antivirals (DAAs) but 50% still had limitations for treatment. (4) Conclusions: Although testing for HBV and HCV was good, testing for HAV is insufficient. Vaccination against HBV and especially against HAV has room for improvement; furthermore, HCV treatment access needs to overcome restrictions.

City Clinical Hospital of Infectious Diseases 220002 Minsk Belarus

Clinic for Infectious Diseases Republic of Srpska Banja Luka 78000 Banja Luka Bosnia and Herzegovina

Clinic for Infectious Diseases University Clinical Center Sarajevo 71000 Sarajevo Bosnia and Herzegovina

Clinic of the Gromashevsky Institute of Epidemiology and Infectious Diseases 01001 Kyiv Ukraine

Department for AIDS Specialized Hospital for Active Treatment of Infectious and Parasitic Diseases Medical University of Sofia 1606 Sofia Bulgaria

Department of Adults' Infectious Diseases Hospital for Infectious Diseases Medical University of Warsaw 02 091 Warsaw Poland

Department of Infectious Disease Faculty of Medicine Medical University of Tirana 1000 Tirana Albania

Department of Infectious Diseases 1st Faculty of Medicine Charles University Prague and Faculty Hospital Bulovka 18000 Prague Czech Republic

Department of Infectious Diseases and Clinical Microbiology Medical Faculty Ege University 35100 Izmir Turkey

Department of Infectious Diseases and Dermatovenerology Faculty of Medicine Vilnius University Vilnius University Hospital Santaros Klinikos LT 08410 Vilnius Lithuania

Department of Infectious Diseases Tartu University Hospital 50406 Tartu Estonia

Department of Infectology and Geographical Medicine 833 05 Bratislava Slovakia

Department of Pharmacology Clinical Pharmacology and Toxicology Faculty of Medicine University of Belgrade 11000 Belgrade Serbia

HIV Unit 4th Department of Internal Medicine School of Medicine National and Kapodistrian University of Athens Attikon University Hospital 12462 Athens Greece

Infectious Diseases AIDS and Clinical Immunology Research Center 0160 Tbilisi Georgia

Lviv Regional Public Health Center HIV Unit 79000 Lviv Ukraine

National AIDS Center 0041 Yerevan Armenia

National Instititue of Hematology and Infectious Diseases National Center of HIV 1097 Budapest Hungary

National Institute of Infectious Diseases Prof Dr Matei Balș 021105 Bucharest Romania

University Hospital of Infectious Diseases 10000 Zagreb Croatia

Victor Babes Clinical Hospital for Infectious and Tropical Diseases 030303 Bucharest Romania

Zobrazit více v PubMed

Sulkowski M.S. Current Management of Hepatitis C Virus Infection in Patients with HIV Co-infection. J. Infect. Dis. 2013;207:S26–S32. doi: 10.1093/infdis/jis764. PubMed DOI PMC

Vallet-Pichard A., Pol S. Hepatitis viruses and human immunodeficiency virus co-infection: Pathogenisis and treatment. J. Hepatol. 2004;41:156–166. doi: 10.1016/j.jhep.2004.05.001. PubMed DOI

Sikavi C., Chen P.H., Lee A.D., Saab E.G., Choi G., Saab S. Hepatitis C and human immunodeficiency virus coinfection in the era of direct-acting antiviral agents: No longer a difficult-to-treat population. Hepatology. 2018;67:847–857. doi: 10.1002/hep.29642. PubMed DOI

DeHovitz J., Uuskula A., El-Bassel N. The HIV epidemic in Eastern Europe and Central Asia. Curr. HIV/AIDS Rep. 2014;11:168–176. doi: 10.1007/s11904-014-0202-3. PubMed DOI

Skrzat-Klapaczyńska A., Matłosz B., Otelea D., Harxhi A., Vassilenko A., Bolokadze N., Rüütel K., Papadopoulos A., Mardarescu M., Youle M., et al. Epidemiological characteristics and access to end-stage liver disease care for HIV-positive patients with HCV and/or HBV coinfections in Central/Eastern European and neighboring countries—data from the ECEE network. Przegl. Epidemiol. 2019;73:61–68. doi: 10.32394/pe.73.07. PubMed DOI

Hepatitis B—Annual Epidemiological Report for 2021. [(accessed on 18 January 2023)]. Available online: https://www.ecdc.europa.eu/en/publications-data/hepatitis-b-annual-epidemiological-report-2021.

Costa-Mattioli M., Allavena C., Poirier A.S., Billaudel S., Raffi F., Ferré V. Prolonged hepatitis A infection in an HIV-1 seropositive patient. J. Med. Virol. 2002;68:7–11. doi: 10.1002/jmv.10163. PubMed DOI

Ida S., Tachikawa N., Nakajima A., Daikoku M., Yano M., Kikuchi Y., Yasuoka A., Kimura S., Oka S. Influence of Human Immunodeficiency Virus Type 1 Infection on Acute Hepatitis A Virus Infection. Clin. Infect. Dis. 2002;34:379–385. doi: 10.1086/338152. PubMed DOI

Vaccine Scheduler | ECDC. [(accessed on 6 December 2022)]. Available online: https://vaccine-schedule.ecdc.europa.eu/

WHO Immunization Data portal. [(accessed on 17 January 2023)]. Available online: https://immunizationdata.who.int/listing.html?topic=&location=

Phung B.-C., Launay O. Vaccination against viral hepatitis of HIV-1 infected patients. Hum. Vaccin. Immunother. 2012;8:554–559. doi: 10.4161/hv.19105. PubMed DOI

Shire N.J., Welge J.A., Sherman K.E. Efficacy of inactivated hepatitis A vaccine in HIV-infected patients: A hierarchical bayesian meta-analysis. Vaccine. 2006;24:272–279. doi: 10.1016/j.vaccine.2005.07.102. PubMed DOI

Laurence J.C. Hepatitis A. and B. immunizations of individuals infected with human immunodeficiency virus. Am. J. Med. 2005;118:75–83. doi: 10.1016/j.amjmed.2005.07.024. PubMed DOI

European Association for Study of Liver EASL Recommendations on Treatment of Hepatitis C 2015. J. Hepatol. 2015;63:199–236. doi: 10.1016/j.jhep.2015.03.025. PubMed DOI

Geddawy A., Ibrahim Y.F., Elbahie N.M., Ibrahim M.A. Direct Acting Anti-hepatitis C Virus Drugs: Clinical Pharmacology and Future Direction. J. Transl. Int. Med. 2017;5:8–17. doi: 10.1515/jtim-2017-0007. PubMed DOI PMC

Macías J., Berenguer J., Japón M.A., Girón J.A., Rivero A., López-Cortés L.F., Moreno A., González-Serrano M., Iribarren J.A., Ortega E., et al. Fast fibrosis progression between repeated liver biopsies in patients coinfected with human immunodeficiency virus/hepatitis C virus. Hepatology. 2009;50:1056–1063. doi: 10.1002/hep.23136. PubMed DOI

Rockstroh J.K., Mocroft A., Soriano V., Tural C., Losso M.H., Horban A., Kirk O., Phillips A., Ledergerber B., Lundgren J. Influence of hepatitis C virus infection on HIV-1 disease progression and response to highly active antiretroviral therapy. J. Infect. Dis. 2005;192:992–1002. doi: 10.1086/432762. PubMed DOI

Reiberger T., Ferlitsch A., Sieghart W., Kreil A., Breitenecker F., Rieger A., Schmied B., Gangl A., Peck-Radosavljevic M. HIV-HCV co-infected patients with low CD4+ cell nadirs are at risk for faster fibrosis progression and portal hypertension. J. Viral. Hepat. 2010;17:400–409. doi: 10.1111/j.1365-2893.2009.01197.x. PubMed DOI

Chandra N., Joshi N., Raju Y.S.N., Kumar A., Teja V.D. Hepatitis B and/or C co-infection in HIV infected patients: A study in a tertiary care centre from south India. Indian J. Med. Res. 2013;138:950–954. PubMed PMC

Ecee Network | Ecee Network. [(accessed on 9 January 2023)]. Available online: https://www.eceenetwork.com/

Chkhartishvili N., Holban T., Simonović Babić J., Alexiev I., Matičič M., Kowalska J., Horban A. State of viral hepatitis care in 16 countries of Central and Eastern European Region. Cent. Eur. J. Public. Health. 2019;27:212–216. doi: 10.21101/cejph.a5486. PubMed DOI

Emerging Opportunities and Challenges for HIV Prevention, Treatment, and Care for MSM in the Former Soviet Union and other Post-Communist States in Eastern Europe—PMC. [(accessed on 17 January 2023)]; Available online: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5522349/ PubMed PMC

Breitschwerdt S., Schwarze-Zander C., Al Tayy A., Mutevelli J., Wasmuth J.-C., Rockstroh J.K. Implementation of EACS vaccination recommendations among people living with HIV. Infection. 2022;50:1491–1497. doi: 10.1007/s15010-022-01827-6. PubMed DOI PMC

Vaccination Coverage against Hepatitis A and B Viruses, Streptococcus pneumoniae, Seasonal Flu, and A(H1N1)2009 Pandemic Influenza in HIV-infected Patients—ScienceDirect. [(accessed on 17 January 2023)]. Available online: https://www.sciencedirect.com/science/article/pii/S0264410×14008044?via%3Dihub. PubMed

Nelson N.P., Allison M.A., Lindley M.C., Brtnikova M., Crane L.A., Beaty B.L., Hurley L.P., Kempe A. Physician Knowledge and Attitudes About Hepatitis A and Current Practices Regarding Hepatitis A Vaccination Delivery. Acad. Pediatr. 2017;17:562–570. doi: 10.1016/j.acap.2017.01.001. PubMed DOI PMC

Tsachouridou O., Georgiou A., Naoum S., Vasdeki D., Papagianni M., Kotoreni G., Forozidou E., Tsoukra P., Gogou C., Chatzidimitriou D., et al. Factors Associated with Poor Adherence to Vaccination against Kepatitis Viruses, Streptococcus pneumoniae and Seasonal Influenza in HIV-Infected Adults. Hum. Vaccin. Immunother. 2019;15:295–304. doi: 10.1080/21645515.2018.1509644. PubMed DOI PMC

Full Article: Vaccine Coverage in PLWH: Disparities and Potential Impact of Vaccine Hesitancy. [(accessed on 31 January 2023)]. Available online: https://www.tandfonline.com/doi/full/10.1080/21645515.2018.1534517. DOI

Peters L., Laut K., Resnati C., Del Campo S., Leen C., Falconer K., Trofimova T., Paduta D., Gatell J., Rauch A., et al. Uptake of hepatitis C virus treatment in HIV/hepatitis C virus-coinfected patients across Europe in the era of direct-acting antivirals. AIDS. 2018;32:1995–2004. doi: 10.1097/QAD.0000000000001928. PubMed DOI

WHO | Global Hepatitis Report. 2017. [(accessed on 22 October 2019)]. Available online: https://www.who.int/hepatitis/publications/global-hepatitis-report2017/en/

Waheed Y., Siddiq M., Jamil Z., Najmi M.H. Hepatitis elimination by 2030: Progress and challenges. World J. Gastroenterol. 2018;24:4959–4961. doi: 10.3748/wjg.v24.i44.4959. PubMed DOI PMC

Dhiman R.K., Premkumar M. Hepatitis C Virus Elimination by 2030: Conquering Mount Improbable. Clin. Liver. Dis. 2021;16:254–261. doi: 10.1002/cld.978. PubMed DOI PMC

Pawlotsky J.-M., Negro F., Aghemo A., Berenguer M., Dalgard O., Dusheiko G., Marra F., Puoti M., Wedemeyer H. EASL recommendations on treatment of hepatitis C: Final update of the series. J. Hepatol. 2020;73:1170–1218. doi: 10.1016/j.jhep.2020.08.018. PubMed DOI

EACS Guidelines. [(accessed on 3 October 2019)]. Available online: http://www.eacsociety.org/guidelines/eacs-guidelines/eacs-guidelines.html.

Management of Acute HCV Infection | HCV Guidance. [(accessed on 15 January 2023)]. Available online: https://www.hcvguidelines.org/unique-populations/acute-infection.

Recently acquired and early chronic hepatitis C in MSM: Recommendations from the European treatment network for HIV, hepatitis and global infectious diseases consensus panel. AIDS. 2020;34:1699–1711. doi: 10.1097/QAD.0000000000002622. PubMed DOI

Clinical Manifestations, Diagnosis, and Treatment of Acute Hepatitis C Virus Infection in Adults—UpToDate. [(accessed on 18 January 2023)]. Available online: https://www.uptodate.com/contents/clinical-manifestations-diagnosis-and-treatment-of-acute-hepatitis-c-virus-infection-in-adults?search=acute%20hepatitis%20c%20treatment&source=search_result&selectedTitle=1~81&usage_type=default&display_rank=1#H58732302.

Short-Duration Pan-Genotypic Therapy with Glecaprevir/Pibrentasvir for 6 Weeks Among People with Recent Hepatitis C Viral Infection—PubMed. [(accessed on 18 January 2023)]; Available online: https://pubmed.ncbi.nlm.nih.gov/31652357/ PubMed

Ledipasvir Plus Sofosbuvir Fixed-Dose Combination for 6 Weeks in Patients with Acute Hepatitis C Virus Genotype 1 monoinfection (HepNet Acute HCV IV): An open-label, single-arm, phase 2 study—PubMed. [(accessed on 18 January 2023)]; Available online: https://pubmed.ncbi.nlm.nih.gov/28029529/ PubMed